Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC.

Nutr Metab (Lond). 2009 Aug 10;6:31. doi: 10.1186/1743-7075-6-31.

2.

Hypometabolism as a therapeutic target in Alzheimer's disease.

Costantini LC, Barr LJ, Vogel JL, Henderson ST.

BMC Neurosci. 2008 Dec 3;9 Suppl 2:S16. doi: 10.1186/1471-2202-9-S2-S16. Review.

3.

Epidermal DNA vaccine for influenza is immunogenic in humans.

Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ.

Vaccine. 2006 May 22;24(21):4475-81. Epub 2005 Aug 19.

PMID:
16150518
4.

Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device.

Roberts LK, Barr LJ, Fuller DH, McMahon CW, Leese PT, Jones S.

Vaccine. 2005 Sep 23;23(40):4867-78.

PMID:
15985318
5.

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ.

Vaccine. 2003 Nov 7;21(31):4604-8.

PMID:
14575774
6.

Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B.

Swain WE, Heydenburg Fuller D, Wu MS, Barr LJ, Fuller JT, Culp J, Burkholder J, Dixon RM, Widera G, Vessey R, Roy MJ.

Dev Biol (Basel). 2000;104:115-9.

PMID:
11713809
7.

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.

Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, Heydenburg Fuller D.

Vaccine. 2000 Nov 22;19(7-8):764-78.

PMID:
11115698

Supplemental Content

Loading ...
Support Center